Search Contract Opportunities

Prevent IDIQ MATO RFP   13

ID: 75N91023R00024 • Type: Solicitation • Match:  85%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Do the documents mention an incumbent contractor?
I'd like to anonymously submit a question to the procurement officer(s)

Description

Posted: Sept. 16, 2024, 2:06 p.m. EDT
Amendment 02 is to issue minor changes to solicitation, 75N91023R00024, for the PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing. See attached for additional details.
Posted: Feb. 23, 2023, 1:58 p.m. EST
Posted: Jan. 31, 2023, 5:08 p.m. EST
Posted: Jan. 6, 2023, 4:41 p.m. EST
Background
The solicitation, 75N91023R00024, is for the PREVENT Cancer Preclinical Drug Development Program. The program aims to provide a structured approach to drug and vaccine development, from discovery to the clinic. It encompasses three separate multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) pools: PREVENT Efficacy Pool, PREVENT CGMP (Current Good Manufacturing Practice) Pool, and PREVENT Toxicology and Pharmacology Pool.

Work Details
The work includes providing preclinical efficacy and intermediate endpoint biomarkers, preclinical services for biopharmaceutical product development and manufacturing, toxicology and pharmacology testing, and other related services. The contract will cover the approximate period of 11/01/2023 through 10/28/2028. The work will be performed under the supervision of the National Cancer Institute (NCI) and will involve various reporting requirements, including technical progress reports, task order progress reports, study task order reports, and final task order reports.

Period of Performance
The contract will be performed over the period of 11/01/2023 through 10/28/2028.

Overview

Agency
National Institutes of Health (NIH) [HHS]
Response Deadline
Feb. 28, 2023, 10:00 a.m. EST (original: Feb. 21, 2023, 2:00 p.m. EST) Past Due
Posted
Jan. 6, 2023, 4:41 p.m. EST (updated: Sept. 16, 2024, 2:06 p.m. EDT)
Set Aside
None
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
PSC
AN12 - Health R&D Services; Health Care Services; Applied Research
Place of Performance
Not Provided
Source
Open
Current SBA Size Standard
1000 Employees
Est. Level of Competition
Average
Vehicle Type
Indefinite Delivery Contract
On 1/6/23 National Institutes of Health issued Solicitation 75N91023R00024 for Prevent IDIQ MATO RFP due 2/28/23. The opportunity was issued full & open with NAICS 541714 and PSC AN12.
Primary Contact
Name
TAYLOR, RICHARD   Profile
Email
rich.taylor@nih.gov
Phone
+1 717 339 9735

Documents

Posted documents for Solicitation 75N91023R00024

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Opportunity Lifecycle

Procurement notices related to Solicitation 75N91023R00024

Award Notifications

Agency published notification of awards for Solicitation 75N91023R00024

IDV Awards

Indefinite delivery vehicles awarded through Solicitation 75N91023R00024

Incumbent or Similar Awards

Contracts Similar to Solicitation 75N91023R00024

Potential Bidders and Partners

Awardees that have won contracts similar to Solicitation 75N91023R00024

Similar Active Opportunities

Open contract opportunities similar to Solicitation 75N91023R00024

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > NATIONAL INSTITUTES OF HEALTH > NIH NCI
FPDS Organization Code
7529-00316
Source Organization Code
100188082
Last Updated
Sept. 16, 2024
Last Updated By
megan.osele@nih.gov
Archive Date
March 15, 2023